PRAME - A Versatile Marker for Many Applications

Preferentially Expressed Antigen in Melanoma (PRAME) is an autosomal cancer-testis antigen (CTA) gene which has been shown to be expressed in melanoma, various nonmelanocytic malignant neoplasms, including non-small cell lung cancer, breast carcinoma, renal cell carcinoma, ovarian carcinoma, leukemia, synovial sarcoma, and myxoid liposarcoma. Normal healthy tissues are not known to express PRAME except for testis, ovary, adrenals, adrenals, and endometrium.

With the exceptions of testis, ovary, placenta, adrenals, and endometrium tissue, PRAME is not typically expressed in normal healthy tissue.1

PRAME is, however, expressed in the vast majority of primary and metastatic cutaneous melanomas.

In a study of 400 melanocytic lesions, PRAME diffusely expressed in 94.4% of acral melanomas, 92.5% of superficial spreading melanomas, 90% of nodular melanomas, 88.6% of lentigo maligna melanomas, and 35% of desmoplastic melanomas, while most melanocytic nevi

(86.4%), were completely negative for PRAME.2

The study also suggests that immunohistochemistry (IHC) for PRAME provides a “cleaner” microscopic picture as to where a lesion ends, as PRAME usually does not stain normal melanocytes, unlike Melan-A and Sox10.2 Due to PRAME’s predominately restricted expression to cancer cells, this protein may be useful in the evaluation of margin status, particularly in cases with a lentiginous in situ component such as seen in acral and lentigo maligna melanomas.2

PRAME [EPR20330]

Rabbit Monoclonal

Concentrate | Predilute

PRAME is available in the following formats:

Format	Description
Concentrate	0.1, 0.5, 1.0 mL
Predilute	6.0, 20, 25 mL RTU
Q Series*– For Leica BOND-III	25 mL RTU
UltraLine* – For BenchMark	6.0, 25 mL RTU

A New Kind of Antibody for Your Leica Bond

Ready to Use Antibodies for Your Roche Instrument

Visit the Biocare Medical website for more information on PRAME:

Read More

1. Fulton, J, Heery, D. PRAME (Preferentially Expressed Antigen In Melanoma). Atlas of Genetics and Cytogenetics in Oncology and Haematology.

2. Lezcano, C et al. PRAME Expression in Melanocytic Tumors. Am J Surg Pathol. 2018 Nov; 42(11): 1456–1465.

*Q Series™ antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare antibodies by Leica Biosystems. Biocare and Leica Biosystems are not affiliated, associated or related in any way. Leica, Leica Biosystems, BOND-MAX and BOND-III are trademarks of Leica Biosystems.

*UltraLine antibodies are developed solely by Biocare Medical and do not imply approval or endorsement of Biocare’s antibodies by Roche® or VENTANA®.

Biocare and Roche/Ventana are not affiliated, associated or related in any way. Roche®, Ventana®, Benchmark® XT, and Benchmark® Ultra are registered trademarks of Roche.